Electroconvulsive shock ameliorates disease processes and extends survival in huntingtin mutant mice

Mohamed R. Mughal1, Akanksha Baharani2, Srinivasulu Chigurupati1,2, Tae Gen Son1, Edmund Chen1, Peter Yang1, Eitan Okun1, Thiruma Arumugam3, Sic L. Chan2,* and Mark P. Mattson1,4,*

1Laboratory of Neurosciences, National Institute on Aging Intramural Research Program, Biomedical Research Center, Baltimore, MD 21224, USA, 2Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL 32816, USA, 3School of Biomedical Sciences, University of Queensland, Brisbane, Australia and 4Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA

Received October 12, 2010; Revised October 12, 2010; Accepted November 19, 2010

Huntington’s disease (HD) is an inherited neurodegenerative disorder caused by expanded polyglutamine repeats in the huntingtin (Htt) protein. Mutant Htt may damage and kill striatal neurons by a mechanism involving reduced production of brain-derived neurotrophic factor (BDNF) and increased oxidative and metabolic stress. Because electroconvulsive shock (ECS) can stimulate the production of BDNF and protect neurons against stress, we determined whether ECS treatment would modify the disease process and provide a therapeutic benefit in a mouse model of HD. ECS (50 mA for 0.2 s) or sham treatment was administered once weekly to male N171-82Q Htt mutant mice beginning at 2 months of age. Endpoints measured included motor function, striatal and cortical pathology, and levels of protein chaperones and BDNF. ECS treatment delayed the onset of motor symptoms and body weight loss and extended the survival of HD mice. Striatal neurodegeneration was attenuated and levels of protein chaperones (Hsp70 and Hsp40) and BDNF were elevated in striatal neurons of ECS-treated compared with sham-treated HD mice. Our findings demonstrate that ECS can increase the resistance of neurons to mutant Htt resulting in improved functional outcome and extended survival. The potential of ECS as an intervention in subjects that inherit the mutant Htt gene merits further consideration.

INTRODUCTION

Huntington’s disease (HD) is an inherited neurological disorder that includes prominent motor, psychiatric and cognitive symptoms resulting from degeneration of neurons in the striatum and cerebral cortex (1). The genetic defect is the presence of expanded CAG repeats in the huntingtin gene resulting in long (>36) repeats of the amino acid glutamine in the huntingtin protein (Htt) (2,3). The function of normal Htt in neurons is unknown, although it may play roles in axonal and vesicle trafficking (4) and regulation of synaptic activity (5). Htt is widely expressed in neurons throughout the brain, and it remains unclear why striatal medium spiny neurons are particularly vulnerable to mutant Htt. The precise molecular mechanisms by which mutant Htt exerts its toxicity remain unknown, although several pathogenic mechanisms have been proposed including adverse actions on the mitochondrial function and neurotrophic signaling (6). In vulnerable neurons, mutant Htt forms intranuclear inclusions, and a similar protein aggregation process occurs when mutant Htt is expressed in cultured cells and transgenic mice (7,8).

One alteration that is implicated in the demise of striatal and cortical neurons in HD is a deficit in brain-derived neurotrophic factor (BDNF). Analyses of postmortem brain tissue samples from HD patients (9) and from multiple lines of Htt mutant mice (10,11) have demonstrated reduced levels of...
BDNF in the striatum and cerebral cortex. The reduction in BDNF levels may contribute to the degeneration of striatal and cortical neurons because BDNF can protect these neuronal populations against insults relevant to HD in cell culture and animal models (12–14). In addition, elevation of BDNF levels by overexpression of the BDNF gene in the striatum and cortex counteracts the neurodegenerative effects of mutant Htt and extends survival in mouse models of HD (11,15). Moreover, BDNF haploinsufficiency accelerates the neurodegenerative process in Htt mutant mice with the enkephalinergic striatal projection neurons being the most vulnerable to reduced BDNF levels (16). Mutant Htt impairs transcription of the BDNF gene by altering the interactions of the transcriptional regulators REST and cAMP response element-binding protein (CREB) with their DNA regulatory elements (17,18). Consistent with a role for reduced BDNF signaling in HD pathogenesis, dietary energy restriction (10) and environmental enrichment (19) increase BDNF levels in striatum and cortex and retard neurodegeneration in HD mouse models.

Electroconvulsive shock (ECS) is a clinical procedure that improves symptoms in many patients with severe depression (20). ECS treatment has also been reported to be effective in reducing psychiatric symptoms in patients with Alzheimer’s (21) and Parkinson’s (22) diseases. There have been a few case reports describing beneficial effects of ECS treatment of HD including N171-82Q HD mice (10,28), we measured body weights of all mice twice each week. The effects of ECS treatment on body weights of WT and HD mice are shown in Figure 1B. ECS treatment prevented the presymptomatic weight loss that occurred in sham-treated HD mice. ECS had no significant effect on body weight in WT mice; mice in the sham and ECS groups gained weight progressively throughout the course of the experiment (Fig. 1B).

Loss of motor coordination is another hallmark that develops early and worsens as the disease progresses in HD patients and transgenic mouse models of HD (10,29). To determine the impact of ECS on motor function, we subjected 14-week-old mice to rotarod testing. Sham-treated HD mice exhibited highly significant motor dysfunction as indicated by lower falling latencies (time until falling) and greater numbers of falls compared with sham-treated WT mice (Fig. 1C and D). We found that falling latency was significantly greater and the frequency of falling was significantly less in ECS-treated compared with sham-treated HD mice (Fig. 1C and D). Collectively, these data demonstrate that ECS treatment promotes body weight maintenance, ameliorates the severity of motor deficits and extends survival of N171-82Q HD mice.

### RESULTS

#### ECS ameliorates motor deficits and improves survival in N171-82Q HD mice

Previous studies showed that N171-82Q HD mice have an abbreviated lifespan of about 21–22 weeks; they exhibit motor deficits beginning at 14–16 weeks of age (27). To determine whether ECS provides significant clinical benefits in an animal model, we assessed the impact of ECS on the development of behavioral symptoms and the survival of male N171-82Q HD mice. Beginning at 2 months of age, 20 wild-type (WT) and 20 HD mice were randomly assigned to either an ECS treatment group or a sham control group (10 HD and 10 WT mice per group); ECS was administered once weekly. HD mice in the ECS group lived significantly longer, by an average of 2 weeks, compared with HD mice in the sham-treated group (Fig. 1A). Whereas all of the sham-treated mice had died by 22 weeks of age, only 30% of the HD mice subjected to ECS had died. No WT mice in either ECS- or sham-treated groups died during the 200-day course of this study.

Because unintended weight loss is a prominent feature in both HD patients and several transgenic mouse models of HD including N171-82Q HD mice (10,28), we measured body weights of all mice twice each week. The effects of ECS treatment on body weights of WT and HD mice are shown in Figure 1B. ECS treatment prevented the presymptomatic weight loss that occurred in sham-treated HD mice. ECS had no significant effect on body weight in WT mice; mice in the sham and ECS groups gained weight progressively throughout the course of the experiment (Fig. 1B).
the ventricles of 16-week-old ECS-treated HD mice were significantly smaller than the ventricles of sham-treated HD mice, and similar in size to WT mice (Fig. 2D). Collectively, these findings suggest that ECS attenuates brain atrophy by protecting striatal and cortical neurons against the neurodegenerative effects of mutant Htt.

ECS reduces Htt protein aggregation in N171-82Q HD mice

Mutant Htt forms abnormal intracellular aggregates in degenerating neurons in the striatum of N171-82Q HD mice (7–10) that are associated with neuronal dysfunction and death (31,32). We therefore determined whether ECS reduced neuronal degeneration by suppressing Htt aggregate formation. The density of Htt aggregates in the striatum, as measured by image analysis of brain sections immunostained with EM48 antibody, was significantly lower in ECS-treated HD mice in comparison with sham-treated HD mice (Fig. 3). ECS also markedly prevented Htt aggregate formation in the cortex of N171-82Q HD mice (Supplementary Material, Fig. S1). No Htt aggregate formation was detected in brain sections from WT mice (data not shown).

ECS normalizes levels of heat-shock proteins in N171-82Q HD mice

Heat-shock proteins (Hsps) are protein chaperones that prevent misfolding and aggregation of newly synthesized mutant proteins and damaged normal proteins (33). Recent findings suggest that levels of several Hsps decrease in striatal neurons in HD, possibly as the result of sequestration by mutant Htt (34,35). Additional findings suggest that mutant Htt can sequester heat-shock factor 1 (HSF1), a transcription factor responsible for the induction of many Hsps (36). To determine whether reduced aggregation may be attributed to increased expression of Hsps, we measured Hsp70 and Hsp40 in mice that were given a final ECS or sham treatment at 13 weeks of age and killed 1 week later. Levels of both protein chaperones were significantly lower in the striatum of sham-treated HD mice in comparison with sham-treated WT mice (Fig. 4A). This decrease in protein chaperones precedes striatal degeneration that is prominent at 16 weeks (Fig. 2A–C). ECS treatment markedly increased the levels of both Hsp70 and Hsp40 in the striatum (Fig. 4A and Supplementary Material, Fig. S2) and cortex (Supplementary Material, Fig. S3) of HD mice. Note that a trend towards increased Hsp70 and Hsp40 was present in the striatum of WT mice; however, significance was not reached. The elevation of Hsps in the striatum of HD mice was associated.
with an increase in the HSF1 protein (Fig. 4B). In contrast, the level of the glucose-regulated protein Grp78 was not significantly different in the striatum of ECS-treated HD mice in comparison with sham-treated HD mice (Fig. 4C). These results suggest that ECS treatment selectively increases the expression of Hsps in N171-82Q HD mice, possibly by a HSF1-mediated mechanism.

ECS restores BDNF levels in the striatum of N171-82Q HD mice

Previous studies have implicated reduced trophic support as a major pathway contributing to striatal degeneration in HD (37). The transcription of the bdnf gene has been reported to be impeded by mutant Htt protein, and BDNF protein levels are reduced in the striatum of HD patients and transgenic HD mice (9–11,18). ECS can increase BDNF levels acutely (within minutes to a few hours) in the hippocampus and cerebral cortex of normal mice, and this effect of ECS is potentiated by prior ECS treatments (25). We therefore determined the effects of ECS on BDNF levels in the striatum of N171-82Q HD mice that were given a final ECS or sham treatment at 13 weeks of age and killed 1 week later. BDNF protein levels, measured by both immunoblot (Fig. 5A) and enzyme-linked immunosorbent assay (ELISA) (Fig. 5B) analyses, were significantly lower in the striatum of HD mice in comparison with WT mice. BDNF levels were significantly greater in ECS-treated HD mice in comparison with sham-treated HD mice (Fig. 5A and B).

We next measured striatal levels of activated (phosphorylated) Akt and CREB, a kinase and transcription factor involved in BDNF signaling and BDNF transcription induction, respectively. The levels of p-Akt and p-CREB were significantly lower in the striatum of sham-treated HD mice compared with WT mice (Fig. 5C and D). In contrast, levels of p-Akt and p-CREB were similar in the striatum of ECS-treated HD mice and WT mice (Fig. 5C and D), suggesting that ECS can prevent the impairment of Akt- and CREB-mediated signaling caused by mutant Htt. Levels of phosphorylated tropomyosin-related kinase B (TrkB), the high-affinity BDNF receptor, were higher in the striatum of ECS-treated HD mice in comparison with sham-treated HD mice (Fig. 5E) further suggesting that the activation of TrkB receptor signaling upon binding of BDNF is involved in the increase of p-Akt and p-CREB in the striatum of ECS-treated HD mice.
excitotoxins, metabolic stress and mutant Htt (40,41). Studies in which levels of Hsp70 or Hsp40 are selectively increased or decreased have shown that these two chaperones, Hsp70 and Hsp40 in the striatum of HD mice. These results in an animal model of HD showed that once-weekly ECT treatment increases Hsp70 and Hsp40 that likely played a significant role in suppressing Htt misfolding and aggregation. Indeed, we found that the ECS treatment reduces Htt aggregation in striatal (Fig. 3) and cortical (data not shown) cells of HD mice suggesting that ECS interrupts the disease process at an early stage. The ECS-induced increase of Hsp70 and Hsp40 is likely mediated by HSF1, a stress-responsive transcriptional regulator that has been shown to suppress polyglutamine aggregate formation in cellular and mouse models (47).

We found that striatal BDNF levels were markedly reduced in HD mice compared with WT mice, and that BDNF levels were significantly increased in HD mice that had been maintained on long-term ECS treatment compared with sham control HD mice. BDNF is a neurotrophin that plays critical roles in synaptic plasticity and neuronal survival in many brain regions including those affected in HD. Previous studies have shown that endogenous BDNF (16), and BDNF delivered directly or by transgenesis (11−14), can protect striatal and cortical neurons in experimental models of HD. Because BDNF transcription has been reported to be impeded by the misfolded Htt protein and because Hsps reduce the accumulation of misfolded Htt protein, our data suggest that elevation of Hsps may contribute in part to the restoration of the BDNF level in ECS-treated HD mice. Furthermore, as the majority of striatal BDNF is synthesized by cortical neurons (48), the data also implies that mitigation of cortical aggregate formation may lessen the HD’s adverse effects on the basal ganglia.

The elevation of BDNF levels may mediate, at least in part, the retardation of disease onset and extension of survival by ECS in N171-82Q HD mice. Consistent with the latter possibility, it was reported that paroxetine and sertraline, two other anti-depressant treatments that increase BDNF levels in HD mice. Furthermore, as the majority of striatal BDNF is synthesized by cortical neurons (48), the data also implies that mitigation of cortical aggregate formation may lessen the HD’s adverse effects on the basal ganglia.

To elucidate the mechanism by which ECS treatment ameliorates cellular pathology and extends lifespan, we examined neuroprotective proteins that inhibit apoptotic biochemical cascades and preserve the cellular ability to adapt to stress. ECS treatment resulted in elevated levels of the protein chaperones Hsp70 and Hsp40 in the striatum of HD mice. These results in an animal model of HD suggest that ECS treatment can counteract the pathogenic actions of mutant Htt, thereby preserving the viability and function of striatal neurons.

To elucidate the mechanism by which ECS treatment ameliorates cellular pathology and extends lifespan, we examined neuroprotective proteins that inhibit apoptotic biochemical cascades and preserve the cellular ability to adapt to stress. ECS treatment resulted in elevated levels of the protein chaperones Hsp70 and Hsp40 in the striatum of HD mice. These results in an animal model of HD suggest that ECS treatment can counteract the pathogenic actions of mutant Htt, thereby preserving the viability and function of striatal neurons.

The expanded polyglutamine stretch in mutant Htt is thought to trigger a conformational change that leads to partial unfolding or misfolding which, if not corrected by molecular chaperones, can lead to abnormal proteolysis and protein aggregation (42,43). Histopathological comparison showed that ECS treatment resulted in a significant reduction in striatal and cortical Htt aggregation. Misfolding and aggregation of mutant Htt are therapeutic targets since they are early molecular events in the pathogenic cascades that underlie the neurological dysfunction in transgenic HD mice (32). A variety of molecular chaperones have been demonstrated to exert therapeutic effects against various experimental models of the polyglutamine diseases, including HD (44−46). Here we showed that once-weekly ECS treatment increases Hsp70 and Hsp40 that likely played a significant role in suppressing Htt misfolding and aggregation. Indeed, we found that the ECS treatment reduces Htt aggregation in striatal (Fig. 3) and cortical (data not shown) cells of HD mice suggesting that ECS interrupts the disease process at an early stage. The ECS-induced increase of Hsp70 and Hsp40 is likely mediated by HSF1, a stress-responsive transcriptional regulator that has been shown to suppress polyglutamine aggregate formation in cellular and mouse models (47).

DISCUSSION

HD is a progressive neurodegenerative disease for which there is no effective therapy. Because HD is caused by a mutation in the gene encoding Htt, genetic testing can identify patients before they become symptomatic, thus offering the possibility of early interventions that delay or prevent the onset of the disease. In the present study, we show that once-weekly ECS treatments delay disease onset and improve survival by an average of 2 weeks which is comparable with the reported increase in survival in N171-82Q HD mice that were either maintained on an intermittent fasting dietary restriction regimen (10) or treated with antidepressant drugs (38,39). Histological analyses demonstrated a reduction in the neuron loss in the striatum of ECS-treated HD mice compared with sham-treated HD mice. These results in an animal model of HD suggest that ECS treatment can counteract the pathogenic actions of mutant Htt, thereby preserving the viability and function of striatal neurons.

To elucidate the mechanism by which ECS treatment ameliorates cellular pathology and extends lifespan, we examined neuroprotective proteins that inhibit apoptotic biochemical cascades and preserve the cellular ability to adapt to stress. ECS treatment resulted in elevated levels of the protein chaperones Hsp70 and Hsp40 in the striatum of HD mice. Studies in which levels of Hsp70 or Hsp40 are selectively increased or decreased have shown that these two chaperones can protect neurons against insults relevant to HD including excitotoxins, metabolic stress and mutant Htt (40,41).

The expanded polyglutamine stretch in mutant Htt is thought to trigger a conformational change that leads to partial unfolding or misfolding which, if not corrected by molecular chaperones, can lead to abnormal proteolysis and protein aggregation (42,43). Histopathological comparison showed that ECS treatment resulted in a significant reduction in striatal and cortical Htt aggregation. Misfolding and aggregation of mutant Htt are therapeutic targets since they are early molecular events in the pathogenic cascades that underlie the neurological dysfunction in transgenic HD mice (32). A variety of molecular chaperones have been demonstrated to exert therapeutic effects against various experimental models of the polyglutamine diseases, including HD (44−46). Here we showed that once-weekly ECS treatment increases Hsp70 and Hsp40 that likely played a significant role in suppressing Htt misfolding and aggregation. Indeed, we found that the ECS treatment reduces Htt aggregation in striatal (Fig. 3) and cortical (data not shown) cells of HD mice suggesting that ECS interrupts the disease process at an early stage. The ECS-induced increase of Hsp70 and Hsp40 is likely mediated by HSF1, a stress-responsive transcriptional regulator that has been shown to suppress polyglutamine aggregate formation in cellular and mouse models (47).

We found that striatal BDNF levels were markedly reduced in HD mice compared with WT mice, and that BDNF levels were significantly increased in HD mice that had been maintained on long-term ECS treatment compared with sham control HD mice. BDNF is a neurotrophin that plays critical roles in synaptic plasticity and neuronal survival in many brain regions including those affected in HD. Previous studies have shown that endogenous BDNF (16), and BDNF delivered directly or by transgenesis (11−14), can protect striatal and cortical neurons in experimental models of HD. Because BDNF transcription has been reported to be impeded by the misfolded Htt protein and because Hsps reduce the accumulation of misfolded Htt protein, our data suggest that elevation of Hsps may contribute in part to the restoration of the BDNF level in ECS-treated HD mice. Furthermore, as the majority of striatal BDNF is synthesized by cortical neurons (48), the data also implies that mitigation of cortical aggregate formation may lessen the HD’s adverse effects on the basal ganglia.

The elevation of BDNF levels may mediate, at least in part, the retardation of disease onset and extension of survival by ECS in N171-82Q HD mice. Consistent with the latter possibility, it was reported that paroxetine and sertraline, two other anti-depressant treatments that increase BDNF levels in HD mice. Furthermore, as the majority of striatal BDNF is synthesized by cortical neurons (48), the data also implies that mitigation of cortical aggregate formation may lessen the HD’s adverse effects on the basal ganglia.

The expanded polyglutamine stretch in mutant Htt is thought to trigger a conformational change that leads to partial unfolding or misfolding which, if not corrected by molecular chaperones, can lead to abnormal proteolysis and protein aggregation (42,43). Histopathological comparison showed that ECS treatment resulted in a significant reduction in striatal and cortical Htt aggregation. Misfolding and aggregation of mutant Htt are therapeutic targets since they are early molecular events in the pathogenic cascades that underlie the neurological dysfunction in transgenic HD mice (32). A variety of molecular chaperones have been demonstrated to exert therapeutic effects against various experimental models of the polyglutamine diseases, including HD (44−46). Here we showed that once-weekly ECS treatment increases Hsp70 and Hsp40 that likely played a significant role in suppressing Htt misfolding and aggregation. Indeed, we found that the ECS treatment reduces Htt aggregation in striatal (Fig. 3) and cortical (data not shown) cells of HD mice suggesting that ECS interrupts the disease process at an early stage. The ECS-induced increase of Hsp70 and Hsp40 is likely mediated by HSF1, a stress-responsive transcriptional regulator that has been shown to suppress polyglutamine aggregate formation in cellular and mouse models (47).

We found that striatal BDNF levels were markedly reduced in HD mice compared with WT mice, and that BDNF levels were significantly increased in HD mice that had been maintained on long-term ECS treatment compared with sham control HD mice. BDNF is a neurotrophin that plays critical roles in synaptic plasticity and neuronal survival in many brain regions including those affected in HD. Previous studies have shown that endogenous BDNF (16), and BDNF delivered directly or by transgenesis (11−14), can protect striatal and cortical neurons in experimental models of HD. Because BDNF transcription has been reported to be impeded by the misfolded Htt protein and because Hsps reduce the accumulation of misfolded Htt protein, our data suggest that elevation of Hsps may contribute in part to the restoration of the BDNF level in ECS-treated HD mice. Furthermore, as the majority of striatal BDNF is synthesized by cortical neurons (48), the data also implies that mitigation of cortical aggregate formation may lessen the HD’s adverse effects on the basal ganglia.

The elevation of BDNF levels may mediate, at least in part, the retardation of disease onset and extension of survival by ECS in N171-82Q HD mice. Consistent with the latter possibility, it was reported that paroxetine and sertraline, two other anti-depressant treatments that increase BDNF levels in HD mice. Furthermore, as the majority of striatal BDNF is synthesized by cortical neurons (48), the data also implies that mitigation of cortical aggregate formation may lessen the HD’s adverse effects on the basal ganglia.
which functions to replace lost or damaged striatal neurons may contribute to ECS-induced beneficial effects. It has been demonstrated that induction of neurogenesis can slow disease progression in transgenic HD mice (15). One functional consequence of neurogenesis is learning and memory (53), and impaired learning has also been described in different transgenic mouse models of HD (54). Previous studies showed that ECS treatment increased the total number of synapses in adult male rat hippocampus (55, 56). Because a reduction in BDNF levels has been described in the hippocampus of transgenic HD mice (57) and because this neurotrophin has been shown to rescue the deficits in long-term potentiation of synaptic transmission (a cellular correlate of learning and memory) in hippocampal slices from transgenic HD mice (58), it will be interesting to determine whether ECS treatment prevents cognitive impairments in transgenic HD mice.

Interestingly, ECS did not have significant effects on levels of Hsp70, Hsp40 and BDNF in the striatum of WT mice, although there were clear trends towards elevated levels of each of these proteins. Previous studies have shown that BDNF mRNA levels are increased acutely (hours to a few days) in the hippocampus following ECS (59). Other studies have found that BDNF mRNA levels in the hippocampus are elevated 2-fold in rats that had received daily ECS treatments for a 10-day period (60). Another study found that BDNF protein levels were significantly increased in the cortex and striatum of rats after 10 daily ECS treatments (60). In our study, the mice were treated with ECS once weekly for 8 weeks using a 50 mA, 0.2 s ECS stimulus. Our ECS treatment was therefore less frequent than previous studies, which could explain the lesser effect of our treatment regimen on BDNF levels compared with more frequent ECS treatments. Striatal neurons in HD mice may be more sensitive to a low ECS treatment because of their lower threshold for excitability, and hence exhibit a greater increase in levels of BDNF and protein chaperones.

In addition to mitigating both gross brain and neuronal atrophy, ECS treatment also ameliorated the progressive body weight loss in N171-82Q HD mice. The basis for the weight loss in HD mice is not yet clear. BDNF and its receptor, TrkB, play prominent roles in food intake and energy metabolism regulation through central mechanisms involving the hypothalamus (61). The potential role of BDNF in regulation of energy metabolism was first discovered through generation of BDNF−/− mice which display an obese phenotype (62, 63). Subsequently, mutations in bdnf and trkB have been identified in some obese patients (64, 65). Genetic ablation of bdnf in the hypothalamus of adult mice results in hyperphagic behavior.
and obesity (66). Emerging evidence suggests that disturbed functions of the hypothalamus may contribute to some signs and symptoms associated with metabolic alterations in HD patients (67). Further studies are needed to examine whether the body weight loss and its amelioration by ECS involve altered expression of BDNF in the hypothalamus of HD mice. A functional BDNF polymorphism (BDNF Val66Met) was reported to influence the vulnerability to various psychiatric disorders (68). There has been a resurgence of interest in the use of ECS for the treatment of drug-refractory psychiatric disorders, and it is considered safe and effective for the treatment of depression in the elderly, including those with co-morbidities (56). ECS treatments often result in long-lasting clinical improvements in psychiatric symptoms which are correlated with the increased BDNF level (69–71). Several reports describe the beneficial effects of ECS in relieving depression in HD patients (23,72–74) who, in general, have higher suicide rates relative to those with other medical and neurodegenerative diseases (75,76). However, there have been no controlled studies of ECS treatment in symptomatic HD patients, nor any attempts to delay the onset of HD with periodic ECS treatments. Our preclinical findings demonstrate for the first time that ECS treatment slows the progression of the neurodegenerative process caused by mutant Htt in an animal model of HD. ECS treatment resulted in increase in the expression of several adaptive cellular stress response proteins which may promote neuronal survival and plasticity, and so forestall the neurodegenerative process resulting in a delay in the disease onset and life extension. The present findings have significant implications for preventive treatment strategies for individuals that carry the mutant Htt gene.

MATERIALS AND METHODS

Mice and ECS treatment

HD-N171-82Q mice were purchased from the Jackson Laboratories (Bar Harbor, ME, USA) and were maintained on the B6C3F1 background; offspring were identified by PCR analysis using genomic DNA extracted from tail biopsies to distinguish transgene-bearing mice from their WT littermates (27). Mice were maintained under usual laboratory conditions that included ad libitum feeding and drinking, in a non-enriched environment (77). Experiments were performed on 2-month-old male mice that were assigned randomly to control and ECS treatment groups. All procedures were approved by the National Institute on Aging Animal Care and Use Committee. ECS was delivered to mice under isoflurane inhalation anesthesia once a week via bilateral ear clip electrodes using the Ugo Basile, ECS Unit 7801. The stimulus

Figure 5. ECS ameliorates deficits in levels of BDNF, and activated Akt and CREB, in the striatum of HD mice. (A) A representative immunoblot (left) and results of densitometric analysis (right) of BDNF protein levels in striatal tissue samples from ECS- and sham-treated HD and WT mice. *P < 0.001. (B) BDNF protein levels, measured by ELISA analysis, in samples of striatal tissue from ECS- and sham-treated HD and WT mice. *P < 0.05. (C) A representative immunoblot (left) and results of densitometric analysis (right) of phospho-Akt protein levels in striatal tissue samples from ECS- and sham-treated HD and WT mice. *P < 0.05. (D) A representative immunoblot (left) and results of densitometric analysis of phospho-CREB protein (right) levels in striatal tissue samples from ECS- and sham-treated HD and WT mice. *P < 0.05. (E) A representative immunoblot (upper) and results of densitometric analysis of phospho-TrkB protein (lower) levels in striatal tissue samples from ECS- and sham-treated HD and WT mice. Values are the mean and SEM (n = 8–10 mice per group). *P < 0.05.
current was 50 mA and the stimulus duration was 0.2 s (78). The presence of tonic seizures immediately after the shock was confirmed by observing the extension of all limbs and forward head extension that normally last for about 10–15 s in each cohort regardless of the genotype. The sham groups were handled identically to the ECS-treated rats except no current was applied. ECS- and sham-treated mice were returned to their cages 10 min afterwards.

**Rotarod test**

Motor coordination and balance were evaluated at weekly intervals throughout the course of the study using an accelerating rotary rod apparatus (Columbus Instrument, OH, USA) as described previously (10). To exclude the possibility that ECS may negatively impact motor performance, rotarod performance was performed 3 days after ECS. Mice were trained to use the rotarod apparatus during a 2 min trial (4 rpm) on the day before the first day of testing. On test days, mice were placed on the rotarod for three trials for a maximal 4 min at accelerating speeds from 4 to 40 rpm and maintenance at 40 rpm after 4 min. Each trial was separated by a 30 min rest period to alleviate stress and fatigue. Latency to fall and falling times for each mouse were recorded by a trained observer blind to the treatment group of the mice.

**Survival study**

Once motor symptoms appeared the HD mice were examined twice daily in the early morning and late afternoon by an investigator blinded as to treatment group of the mice. Mice unable to right themselves after being placed on their backs, and unable to initiate movement after being gently prodded for 10 min (79) were euthanized; their age at this point was considered the age of death. Deaths that occurred overnight were recorded the next morning.

**Tissue preparation and histologic analysis**

Immediately after being anesthetized with an overdose of isoflurane, mice were perfused transcardially with saline, followed by 4% paraformaldehyde (PFA) in PBS (pH 7.4). Brains were post-fixed in 4% PFA for 24 h, and then cryoprotected in 30% sucrose/PBS for 48 h. Serial coronal sections (10 μm thickness) cut through the entire striatum with a freezing microtome (Microm HM 505 N) were collected on slides. Nissl and Fluorojade C staining were performed as previously described (80) to determine surviving and degenerating neurons, respectively. For Fluoro-Jade staining, the slides were immersed for 3 min in 100% ethanol, for 1 min in 70% ethanol, and for 1 min in distilled water and then incubated in a solution containing 0.01% Fluoro-Jade (Histo-Chem, Inc., Jefferson, AR, USA) and 0.1% acetic acid (1:10) for 30 min on a shaker. After three 10 min washes, the slides were cover slipped.

**Immunohistochemistry**

Serially cut coronal tissue sections were blocked with 5% normal serum in 1% Triton X-100 in PBS for 30 min at room temperature followed by incubation overnight at 4°C with primary antibodies against N-terminal Htt protein (EM48, Chemicon; 1:400 dilution), NeuN (Chemicon; 1:400 dilution) and DARPP-32 (Abcam; 1:500 dilution). Tissue sections were incubated with Alexa568- or Alexa488-conjugated secondary antibodies (1:200, Molecular Probes) appropriate for the specific primary antibodies. The sections were then washed with 0.05% Tween-20 in phosphate-buffered saline for 1 h and counterstained with 4',6-diamidino-2-phenylindole (50 ng/ml) for 30 s, washed and mounted in FluorSave medium (Calbiochem).

**Quantification of Htt aggregates and neurons**

Images of EM48-positive neuronal inclusions and DARPP-32, Nissl or Fluorojade C-stained neurons were obtained by scanning 10–12 coronal sections spread over the anterior–posterior extent of the striatum (inter-section distance: 400 μm), using a 20× objective on a Nikon 80i Research Upright Microscope equipped with image acquisition software (Qimaging Retiga 2000). All images were segmented using the same light threshold, mask smoothing and object size filters. Total area of pixel intensity was measured with the automated measurement tools in IP lab software (BD Biosciences Bio-imaging). The total density was averaged and expressed as normalized, corrected OD. Labeled cells were counted throughout the depth of the section for four adjacent fields of each section. All brain specimens were coded and analyses were performed by an investigator blinded as to the genotype and treatment group of the mice.

**Immunoblotting**

Methods for protein quantification, electrophoretic separation and transfer to nitrocellulose membranes were described previously (62). Membranes were incubated in blocking solution (5% milk in Tween Tris-buffered saline; TTBS) overnight at 4°C followed by a 1 h incubation in primary antibody diluted in blocking solution at room temperature. Membranes were then incubated for 1 h in secondary antibody conjugated to horseradish peroxidase (Vector Laboratories) and bands were visualized using a chemiluminiscence detection kit (ECL, Amersham). Membranes were stripped and re-probed with the actin antibody to verify and normalize protein loading (50 μg total protein, unless stated otherwise). For immunodetection of blots, enhanced chemiluminescence (ECL, Amersham) was applied. Immunoreactive bands were quantified using NIH Image software. Information on the primary antibodies used in this study, including the source, dilution and molecular weight of the antigen, can be found in Supplementary Material, Table S1.

**Statistical analysis**

Kaplan–Meier survival data were analyzed using the log-rank test for trend. All other data were analyzed using one-way
ANOVA with Dunnett’s *post hoc* test for pairwise comparisons or Student’s *t*-test as appropriate. These statistical analyses were performed using GraphPad Prism version 5.00 for Windows (GraphPad Software, San Diego, CA, USA). *P*-values ≤ 0.05 were considered significant.

**SUPPLEMENTARY MATERIAL**

Supplementary Material is available at HMG online.

**Conflict of Interest statement.** None declared.

**FUNDING**

This research was supported by the Intramural Research Program of the National Institute on Aging of the National Institutes of Health, and by NIH grant (1R21NS066265-01) to S.L.C.

**REFERENCES**


